Paclitaxel (Taxol) is a promising frontline chemotherapeutic agent for the treatment of human breast and ovarian cancers. The adenoviral type 5 E1A gene has been tested in multiple clinical trials for its anticancer activity. E1A has also been shown to sensitize paclitaxel-induced killing in E1A-expressing cells. Here, we show that E1A can sensitize paclitaxel-induced apoptosis in breast cancer cells in a gene therapy setting by an orthotopic mammary tumor model. We first showed that expression of E1A enhanced in vitro paclitaxel cytotoxicity, as compared to the control cells. We then compared the therapeutic efficacy of paclitaxel between orthotopic tumor models established with vector-transfected MDA-MB-231 (231-Vect) versus 231-E1A stable cells, using tumor weight and apoptotic index (TUNEL assay) as the parameters. We found paclitaxel was more effective in shrinking tumors and inducing apoptosis in tumor models established with stable 231-E1A cells than the control 231-Vect cells. We also tested whether E1A could directly enhance paclitaxel-induced killing in nude mice, by using a nonviral, surface-protected cationic liposome to deliver E1A gene via the mouse tail vein. We compared the therapeutic effects of E1A gene therapy with or without Taxol chemotherapy in the established orthotopic tumor model of animals inoculated with MDA-MB-231 cells, and found that a combination of systemic E1A gene therapy and paclitaxel chemotherapy significantly enhanced the therapeutic efficacy and dramatically repressed tumor growth (Po.01). In addition, survival rates were significantly higher in animals treated with combination therapy than in the therapeutic control groups (both Po.0001). Thus, the E1A gene therapy indeed enhances the sensitivity of tumor cells to chemotherapy in a gene therapy setting and, the current study provides preclinical data to support combination therapy between E1A gene and chemotherapy for future clinical trials.
A mplification and overexpression of Her-2/neu (or c-erbB-2) oncogene have been found in approximately 25% of human breast carcinomas and associated with poor prognosis. 1 Using Her-2/neu as a target for the development of therapeutic agents proves to be an effective approach. For example, Herceptin, a humanized monoclonal antibody against Her-2/neu, has demonstrated its efficacy by either Herceptin alone or in combination with cisplastin as a first-line therapy for the treatment of breast cancer patients with advanced disease whose tumors overexpressed Her-2/neu.
2, 3 We have previously reported that the adenoviral type-5 E1A gene product also repressed Her-2/neu oncogene overexpression and suppressed the tumorigenic and metastatic potential of Her-2/neu-transformed cells. 4 The adenoviral type-5 and type-2 E1A were reported originally as oncogenes, which could cooperate with other viral and cellular oncogenes to transform primary culture cells but not established cell lines, distinct from the type-12 E1A, a potent oncogene that can transform established cell lines. 5 However, E1A has not been associated with human malignancies despite extensive studies trying to identify such a link. Instead, E1A was shown to suppress experimental metastasis of rodent cells transformed by the ras oncogene [6] [7] [8] and the Her-2/neu oncogene 9 and metastasis of certain human cancer cell lines. 10 In addition, increasing experimental data indicate that E1A was able to inhibit the tumorigenicity of the transformed rodent cells as well as of the human cancer cell lines. 5, 10 Therefore, based on its ability to suppress both tumorigenicity and metastasis, E1A has been considered as a tumor suppressor gene 5, [11] [12] [13] and translated into multiple clinical trials. [14] [15] [16] In addition to the tumor suppressor activities, expression of the E1A gene in stably transfected normal fibroblast and human cancer cells has also been shown to increase sensitivity to the in vitro cytotoxicity of several anticancer drugs, such as etoposide and cisplatin in normal fibroblasts and sarcoma cells, Adriamycin in colon and hepatocellular carcinoma cells, Gemcitabine in hepatocellular and breast cancer cells, and paclitaxel in breast and ovarian cancers. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Our previous studies demonstrated that E1A can sensitize paclitaxel-induced cell killing in Her-2/neu-overexpressing cancer cells. 22, 23 We did not observe E1A-induced paclitaxel sensitization for Her-2/neu low-expressing cells under the same condition, in which the paclitaxel concentration is too high to observe sensitization effect in the Her-2/neu low-expressing cells (please see Discussion later). 22 However, in our recent study, we found that expression of E1A in Her-2/neu low-expressing breast cancer MDA-MB-231 and MCF-7 cells sensitized cells to different categories of anticancer drug-induced apoptosis at a varying extent, these drugs include paclitaxel, cisplatin, Adriamycin, Gemcitabine, and methotrexate. 26 Since these drugs exert there anticancer activity through different modes of actions, we showed that E1A-mediated sensitization to different types of anticancer drug-induced apoptosis was achieved through a general cellular pathway that regulate the cell survival and cell death signalings. 26 In the current study, we further examine the E1A-induced chemosensitization for the Her-2/neu low-expressing cancer cells in a mammary tumor model using the newly developed systemic nonviral delivery system SN, which contains a surface-protection polymer to stabilize the liposome-DNA particles for intravenous (i.v.) injection. [28] [29] [30] We tested if combination of E1A gene therapy with paclitaxel chemotherapy will enhance the cytotoxicity and antitumor effect of paclitaxel in an orthotopic breast cancer xenograft established by inoculation of low Her-2/neu-expressing MDA-MB-231 cells in nude mice. We found that combination of systemic E1A gene therapy with paclitaxel significantly enhanced paclitaxel-induced apoptosis and prolonged animal survival rates in the orthotopic model in vivo. Thus, the current study provides further experimental support for combination therapy between E1A gene therapy and paclitaxel chemotherapy.
Materials and methods

Cell lines
Human breast cancer MDA-MB-231 and MCF-7 cells were grown in Dulbecco's modified Eagle's medium/F-12 (Life Technologies Inc., Rockville, MD) supplemented with 10% fetal bovine serum. The stable E1A-expressing cell lines were established as previously described. 31 
Paclitaxel
A stock solution of paclitaxel (Taxol, Bristol-Myers Squibb Co., Princeton, NJ) was stored at À801C before use. For in vitro use, paclitaxel was diluted in serum-free medium at the required concentration. For in vivo use, paclitaxel was diluted in normal saline (NS) to a dose of 10 mg/kg in 150 ml per injection, once a week for 6 weeks.
Formulation
The gene-delivery system, termed SN, was described by Zou et al. 28, 29 The DNA was entrapped in the SNliposome after the thin-lipid film was hydrated and extruded through a filter with 0.2-mm-diameter pores (Gelman Sciences; Ann Arbor, MI).
MTT assay
The metabolic conversion of tetrazolium salt (MTT) to formazan was used to indirectly measure the number of viable cells after exposure to Taxol. Cells (3 Â 10 3 /well) were seeded in triplicate in 96-well culture plates in 0.2 ml of culture medium and allowed to adhere for 24 hours. After exposure to Taxol for the indicated time periods, 20 ml of MTT was added to each well. Cells were cultured for an additional 2 hours, and 100 ml of extraction buffer (20% SDS in 50% N,N-dimethyl formamide, pH 4.7) was added to the culture medium. The cells were incubated overnight at 371C, and the plate absorbency was measured at 570 nm.
Propidium iodide staining and FACS analysis
Samples of 2 Â 10 6 cells were collected, washed once with phosphate-buffered saline (PBS), and fixed with 70% icecold ethanol overnight. After fixation, cells were washed with PBS to remove residual ethanol, pelleted, and resuspended in PBS containing 50 mg/ml of propidium iodide (Sigma, St Louis, WA). The staining was performed at 41C for at least 30 minutes, and samples were analyzed using a FACScan (Becton-Dickinson, San Jose, CA) in the core facility at The University of Texas M.D. Anderson Cancer Center.
Athymic nude mice
Female athymic BALB/c-nu/nu mice, 4-6 weeks old, were purchased from Charles River Laboratories (Wilmington, MA). The animals were allowed to acclimate for 7 days before the study initiation. All of the animals were housed under pathogen-free conditions, and were given water and chow ad libitum. Animal care and use were in accordance with Institutional and NIH guidelines.
Establishment of orthotopic breast cancer model and systematic E1A gene therapy in nude mice MDA-MB-231 cells (1 Â 10 6 cells/0.1 ml) or 231-E1A cells (2 Â 10 6 cells/0.1 ml) were subcutaneously injected into the mammary fat pad (m.f.p.) of female, athymic mice. Tumors were allowed to develop for 21 days and mice were then randomly grouped and treated with SNliposome alone (SN, i.v.), Taxol alone (i.p., 10 mg/kg/ injection, once a week for 6 weeks), E1A alone (i.v., 15 mg/mouse/injection, injection into mouse tail vein twice a week for 6 weeks), or E1A (i.v., 15mg/mouse/injection) plus Taxol (i.p., 10 mg/kg/injection, 24 hours after E1A injection, for 6 weeks). Both maximum and minimum diameters of the resulting tumors were measured twice a week using a slide caliper. Tumor volumes were calculated by assuming a spherical shape and using the formula, volume ¼ 4/3r 3 , where r ¼ 1/2 of the mean tumor diameter measured in two dimensions. The mice were killed when their tumors were larger than 2 cm in diameter; otherwise, they would keep growing and would remain as subjects for survival rate analysis.
Immunohistochemical analysis
To evaluate expression of E1A in stable MDA-MB-231 cells, cells in exponential growing were harvested and washed with PBS twice and then cytospuned. Cytospun cells were fixed for 10 minutes in 4% formaldehyde (Sigma), washed with PBS, dried, and stored at À801C or subject to immunohistochemical analysis. To evaluate expression of E1A protein level in tumor tissues in vivo, stable E1A-expressing cells or control vector cells were inoculated into m.p.f. of nude mice. After a palpable tumor was formed, in approximately 4-6 weeks, the tumor was dissected and fixed in 10% formalin and embedded in paraffin blocks. Paraffin-embedded sections were then pretreated with dewax and rehydrated. They were washed in xylene and rehydrated through a graded series of ethanol and redistilled water. The paraffin sections or cytospun slides were incubated with E1A M73 monoclonal antibody (Oncogene Science, Inc., Cambridge, MA) diluted 1:20. The slides were then incubated with biotinylated goat anti-rabbit IgG (Vector Laboratories) or biotinylated horse anti-mouse IgG (Vector Laboratories) diluted 1:200 in PBS. The slides were then incubated with an avidin-biotin-peroxidase complex (Vector Laboratories), and the peroxidasecatalyzed product was visualized with 0.125% aminoethyl carbazole chromogen buffer (Sigma Chemical Co.).
In vivo apoptotic (TUNEL) assay
For in vivo apoptotic assay, tumors were fixed in 10% formalin and embedded in paraffin blocks as described above. Tissue sections were incubated with proteinase K (20 mg/ml in 10 mM Tris/HCl, pH 7.4-8.0, for 15 minutes at 371C), permeabilized in 0.1% Triton-X-100 in 0.1% sodium citrate, and then labeled with the TUNEL (deoxynucleotide transferase-mediated dUTP-biotin nick end labeling) reaction mixture (Boehringer Mannheim, Indianopolis, IN), according to the manufacturer's protocol. Briefly, biotinylated nucleotide mix and TdT enzyme were added and incubated for 1 hour at 371C; slides were washed in PBS, blocked in hydrogen peroxide, and incubated in streptavidin horseradish peroxidase. The slides were developed in 3,3 0 -diaminobenzidine and counterstained with hematoxylin. The apoptotic cells (brown staining) were counted under a microscope. The apoptosis index was defined by the percentage of brown cells among the total cells of each sample. In total, 10 fields with 4200 cells in each were randomly counted for each sample.
Results
E1A-mediated sensitization to paclitaxel correlated with E1A-induced apoptosis in vitro
To test whether E1A can sensitize cells to paclitaxelinduced apoptosis in low Her-2/neu-expressing cells in cell culture in vitro, we treated MDA-MB-231 (p53 mutant) and MCF-7 (p53 wild type) human breast cancer cell lines and their E1A-expressing stable cells with different dosages of paclitaxel and performed MTT cytotoxicity assays. We found that stable expression of wild-type E1A enhanced sensitivity to paclitaxel-induced killing in MDA-MB-231 cells in a dose-dependent manner. Compared with their IC 50 dosage, the E1A-expressing stable cells were 10 times more sensitive than that of the paclitaxel-treated parental or vector-transfected control cells (Fig 1a) . Stable expression of E1A also enhanced the sensitivity of MCF-7 cells to paclitaxel, although to a lesser extent. Interestingly, a revertant of the MCF-7 clone that lost its E1A expression during the long-term in vitro cell culture also lost its sensitivity to paclitaxel (Fig  1b) . Three additional independent E1A stable clones from each cell line were analyzed, all of which expressed high levels of E1A protein and showed similar sensitivity to paclitaxel (data not shown).
To address whether apoptosis was involved in E1A-mediated sensitization to paclitaxel, we examined the presence of poly (ADP-ribose) polymerase (PARP) cleavage as an apoptotic cell death marker. We detected a dose-dependent increase of PARP cleavage in E1A-expressing MDA-MB-231 (231-E1A) and MCF-7 (MCF-7-E1A) cells upon treatment with 0.1-0.001 mM paclitaxel. In parental and 231-Vect cells, however, PARP cleavage was observed only upon treatment with 0.1 mM paclitaxel, while in the revertant MCF-7 cell clone, it was not detected (Inset , Fig 1a and b) . Fluorescence-activated cell sorting (FACS) analysis also supported that E1A enhanced paclitaxel-induced apoptosis, as demonstrated by an increased proportion of sub-G1-phase cells in E1A-expressing cell lines (Fig 1c) . Thus, E1A-mediated sensitization to paclitaxel in breast cancer MDA-MB-231 and MCF-7 cells is consistent to the previous report for E1A-mediated sensitization to multiple chemotherapeutic drugs.
26,32
Expression of E1A enhances paclitaxel-induced antitumor effect in vivo To test whether E1A also mediated sensitization to paclitaxel in vivo, we inoculated stable E1A-expressing (231-E1A) and vector-transfected (231-Vect) MDA-MB-231 cells into mouse m.f.p. In our pilot study, we inoculated the same amount of MDA-MB-231 and 231-E1A cells into mouse m.f.p. and observed that few of the animals with inoculation of the 231-E1A cells developed tumor and even though in some cases, the tumors developed, they are much smaller than those of the MDA-MB-231 cells (data not show). Therefore, in order to ensure tumor formation with comparable size in 231-E1A-inoculated animals, twice the amount of 231-E1A (Fig 2A, Po.01) , even though twice the amount of cells were originally inoculated in the 231-E1A group. The result supported the previous reports that expression of E1A alone had a significant effect on repression tumor growth in vivo independent of Her-2/neu status. 18, 33 Treatment with These results indicate that paclitaxel alone is sufficient to achieve a 50% cytoreduction of tumor mass in comparison with mice treated with normal saline (NS) (Fig 2A) .
Comparing the percentage of tumor shrinkage in paclitaxel-treated 231-Vect tumor group, paclitaxel treatment of 231-E1A tumor achieved a better tumor shrinkage than that of the paclitaxel-treated 231-Vect animals, that is, the 231-E1A group was more sensitive to Taxol (Po.01). Thus, expression of E1A also sensitized paclitaxel cytotoxic effect in established tumors in vivo.
To test whether E1A was still expressed in tumor tissue in vivo, we then analyzed E1A expression in tumor tissue slides and used original 231-E1A stable cells prepared by using cytospun as the positive control by immunohistochemistry. Modest to strong E1A staining was detected in more than 90% of 231-E1A stable cells cultured in vitro in the cytospun slides (Fig 2B) . However,less than half of the cells were positive for E1A staining in tumor tissue samples obtained from the original 231-E1A inoculated animals, most of them only had modest or weak staining of E1A (Fig 2B) . This result suggests that most of the cells with higher E1A expression were lost under the in vivo selection pressure during tumor development. None of the control 231-Vect stable cells or 231-Vect inoculated tumors had a positive staining for E1A (Fig 2B) . These results also suggest that expression of E1A repressed tumor growth in vivo, while loss of E1A expression may result in tumor development in 231-E1A stable cells.
E1A-mediated sensitization to paclitaxel correlated with E1A-induced apoptosis in vivo
To test if E1A-mediated sensitization to paclitaxel cytotoxicity in vivo also occurs through apoptotic cell death, we used a TUNEL assay to compare apoptotic index in paclitaxel-treated tumor tissue samples obtained from animals inoculated with 231-E1A cells versus those from animals inoculated with 231-Vect cells. In order to detect apoptotic cells in vivo following paclitaxel treatment, tumor-bearing animals were treated with paclitaxel (15 mg/kg/animal) once by i.p. injection. Animals were killed 24 hours after paclitaxel treatment and tumor tissue samples were then collected and sectioned for TUNEL assay. In tumor tissues obtained from 231-E1A-inoculated animals (n ¼ 3), a few TUNEL-positive cells were detected without treatment with paclitaxel; however, treatment with paclitaxel remarkably increased TUNELpositive cells (from 9 to 18% positive cells). Treatment with paclitaxel also enhanced TUNEL-positive cells in tumor tissue samples obtained from 231-Vect-inoculated animals (n ¼ 3) (from 3% without paclitaxel to 7% with paclitaxel) (Fig 3A and B) . Statistic analysis showed that paclitaxel-treated 231-E1A tumor tissues had a significantly higher percentage of TUNEL-positive cells than did paclitaxel-treated 231-Vect tumor tissues (Po.001).
Again, the result suggests that expression of E1A significantly enhanced paclitaxel cytotoxicity in tumor tissue in vivo. The relatively higher frequency of TUNELpositive cells detected in tumor tissues obtained from 231-E1A-inoculated animals also suggests that the relatively small tumors formed in 231-E1A-inoculated animals in Figure 2A may in part be due to the enhanced apoptosis in 231-E1A tumors.
Enhancement of paclitaxel-induced antitumor effect by systemic delivery of E1A gene in an orthotopic breast cancer model in vivo
To explore whether E1A could directly enhance paclitaxel-induced killing in a gene therapy setting in vivo, we designed systemic E1A gene therapy experiments in mice by i.v. injection of liposome encapsulated E1A gene via the mouse tail vein with or without combination of paclitaxel chemotherapy. MDA-MB-231 cells were inoculated orthotopically into mouse m.f.p. and were allowed to grow until a palpable tumor was formed. When tumors were established, animals were regrouped and randomly assigned to each experimental group. We used SN-liposome formulation as our gene-delivery system because of its relatively high efficiency in vivo.
28
SN-liposome (SN) or SN-liposome encapsulated E1A gene was given twice a week for 6 weeks through mouse tail vein, while paclitaxel was given once a week by intraperitoneal injection for 6 weeks. We started to monitor tumor size once a week when animals received each treatment the first time and continued until 6 weeks later after each treatment ended (total for 12 weeks). We then compared the mean tumor volume between each treatment group in order to assess the therapeutic effects of each treatment regime. Compared with control SNliposome alone, treatment with either systemic delivery of E1A gene or i.p. injection of paclitaxel repressed tumor growth during the 12-week observation period (Po.05, Po.01) (Fig 4) . Compared with treatment of systemic E1A gene alone or paclitaxel alone, a combination of E1A gene therapy and paclitaxel chemotherapy produced significantly enhanced therapeutic effects of paclitaxel and dramatically repressed tumor growth (both Po.0001) (Fig 4) . In addition, tumors were completely eradicated in four out of seven mice treated with combination therapy. Thus, combination of systemic E1A gene therapy with paclitaxel chemotherapy had a synergistic effect in repressing tumor growth in the orthotopic breast cancer model in vivo. Although E1A-liposome alone did not dramatically repress tumor growth as that of paclitaxel alone did (Fig 4) , treatment with systemic delivery of E1A gene achieved a comparable enhancement than that of the animals treated with paclitaxel alone in terms of prolongation of the animal survival times (Po.05) ( Fig  5) . Compared with survival rate of animals with treatment of SN-liposome, treatment with either E1A gene or paclitaxel had a longer survival time (both Po.05). In nearly a year's close observation, we found that combination of systemic E1A gene therapy with paclitaxel chemotherapy achieved a significantly better outcome in animals survival rates, compared with all the three single treatment regimes, including SN-liposome alone, liposome-E1A, or paclitaxel (all Po.01) (Fig 5) . In addition, three out of seven animals treated with combination therapy achieved over 1 year's tumor-free survival. Thus, the combination of systemic E1A gene therapy with paclitaxel chemotherapy significantly enhanced paclitaxel's antitumor effect and dramatically prolonged animal survival rates in the orthotopic breast cancer model in vivo.
Discussion
In the current study, we showed that E1A mediated sensitization to the paclitaxel-induced apoptosis in vitro in low Her-2/neu-expression breast cancer MCF-7 and MDA-MB-231 cells. We showed that expression of E1A also enhanced the therapeutic effect of paclitaxel in an orthotopic breast cancer model in vivo. In addition, we demonstrated that combination of a systemic E1A gene therapy using a surface-protected SN-liposome-E1A complex formulation with paclitaxel chemotherapy significantly enhanced paclitaxel's antitumor effect and dramatically prolonged animal survival rates in an orthotopic breast cancer animal model. Our data showed that the combination of both E1A gene therapy and paclitaxel chemotherapy is much more efficient than either E1A gene therapy or paclitaxel alone in terms of repression of tumor growth in vivo and prolongation of animal survival rate. Unlike the trials on Her-2/neu overexpression tumors that used Her-2/neu expression as the marker, test on low Her-2/neu expression tumors may need a surrogate marker or markers in order to monitor whether the therapy works in this subgroup of tumors. In Enhanced paclitaxel efficacy by systemic delivery of the E1A gene Y Liao et al the literature, previous studies on E1A-mediated sensitization to drug-induced apoptosis in different cell systems or cell-free systems have identified a few other molecules that are also linked to E1A-mediated chemosensitization other than downregulation of Her-2/neu, such as the proapoptotic protein Bax, Apaf-1, p19ARF, procaspase-2, -3, -7, -8, and -9, cell cycle inhibitor p21
Cip1/WafÀ1
, or as yet unidentified inhibitor that ordinarily provides protection against cell death. 23, 32, [34] [35] [36] [37] [38] [39] [40] [41] Whether one of these molecules or other unknown molecules could be used as a surrogate marker to monitor the therapeutic effect of this combination therapy in tumors with low Her-2/neu expression needs further assessment.
It is worthwhile mentioning the important clinical implications of the concentration of paclitaxel that we tested in the in vitro study because the paclitaxel concentration that can kill cancer cells in vitro, in the presence of E1A, is clinically relevant. A plasma concentration of 5 -10 mM paclitaxel can be achieved after bolus infusion of paclitaxel, but it rapidly falls to a level of several hundred nanomolar or less. 42 Our experiments showed that 10 nM paclitaxel was sufficient to induce apoptosis in vitro in E1A-expressing cells but not in parental or vector control cells (Fig 1) . This indicates that a clinically relevant concentration (5B200 nM) of paclitaxel is sufficient to kill E1A-expressing cells, but parental cells require much higher dosage, which may be difficult to be achieved in a clinical setting. 42 We have previously shown that Her-2/neu-overexpressing cells are resistant to paclitaxel-induced apoptosis 43, 44 and E1A, through downregulation of Her-2/neu, can sensitize cellular response to paclitaxel-induced apoptosis. 22, 23, 43, 44 In those studies, we could not detect E1A-mediated chemosensitization in the low Her-2/neu-expressing cells. 22 The major reason for this discrepancy was due to the paclitaxel concentrations tested. The Her-2/neuoverexpressing cancer cells are resistant to paclitaxel even at a dosage of 10.0 mM, in the presence of E1A, they became sensitive even at the dose of 1.0 mM of paclitaxel. 22, 23 The low Her-2/neu-expressing cells, such as MDA-MB-231and MDA-MB-435, are much more sensitive to paclitaxel, even at paclitaxel concentration of 0.1 mM they are still sensitive. 22 Therefore, in the previous studies, the dose of paclitaxel was too high (1 mM) to detect E1A-mediated paclitaxel sensitization that became detectable in the present study (0.01 mM). Thus, the E1A gene therapy strategy may represent a novel and unique way to Enhanced paclitaxel efficacy by systemic delivery of the E1A gene Y Liao et al enhance the sensitivity of tumor cells to chemotherapy and the current study provides solid preclinical data that may help in developing further clinical trials using the combination of chemotherapy with systemic gene therapy.
